Long‐term efficacy and safety results from an open‐label phase <scp>III</scp> study (<scp>UNCOVER</scp>‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

Abstract

In patients withdrawn from ixekizumab after achieving PASI75, approximately half relapsed within 5 months of withdrawal; however, most patients recaptured response within 12 weeks, and response was maintained for up to 120 weeks of retreatment.